Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
13 evidence topics · 11 sources
Skeletal-related events in patients with bone metastases
“BM is associated with accelerated bone resorption leading to increased morbidity due to a range of skeletal-related events (SREs) including bone pain (BP), pathological fracture (PF), spinal cord compression (SCC), tumor-induced hypercalcemia (TIH) and surgery or radiation therapy (RT) to bone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies have demonstrated that at least one SRE occurs in nearly 50% of patients with bone metastases of breast cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In randomized trials in advanced breast cancer, one of the major SREs occurs on average every 3–6 months after the onset of BM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevention of skeletal-related events with bone-modifying agents
“Patients with breast cancer who have evidence of bone metastases should be treated with BMAs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The analgesic effects of BMAs are modest, and they should not be used alone for bone pain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ESMO recommendations on bone metastases and skeletal-related events
Visceral crisis: prognosis
“The diagnosis of visceral crisis in metastatic breast cancer is associated with poor prognosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sbitti et al. showed a median Overall Survival (mOS) of 4.7 weeks in a retrospective cohort of 35 patients with hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer and visceral crisis pre-treated with two hormonal therapy lines, of whom 77 % had liver metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, the type of organic involvement in patients with VC is an established prognostic factor, with hepatic involvement being more associated with worse mOS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: incidence by subtype and line of therapy
“Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2- disease, 23% for HR+/HER2+ disease, 34% for HR-/HER2+ disease, and 22% for triple-negative breast cancer (TNBC).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Brain metastases incidence increases per line of therapy for every MBC subtype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: pooled incidence in HR-positive, HER2-negative disease
“Four studies including 14656 patients reported the incidence of brain metastases specifically in patients with HR+/HER2− MBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled cumulative incidence of brain metastases among this subgroup was 0.15 (95% CI: 0.078–0.27), with a median follow-up of 33.0 months (IQR: 31.9–36.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: detection by screening MRI and ABC8 position
“Data from a non-randomized, prospective screening study in patients with ABC reveal that approximately one-quarter of patients across all subtypes (HR+/HER2-negative, TNBC, and HER2+) who undergo a baseline and 6-month screening MRI will be diagnosed with brain metastases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As we await these data, the existing evidence base, though limited, provides rationale to consider screening in patients at high risk of developing brain metastases and in situations where the knowledge of brain metastases status would impact the choice of systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system metastases: rising incidence with longer survival
“The incidence of brain metastases in breast cancer patients is increasing mainly due to improved systemic therapies resulting in more durable control of extracranial metastatic disease and prolonged survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease progression: shorter benefit from endocrine monotherapy after first line
“Although most HR-positive breast cancers benefit from first-line ET, most eventually become endocrine-resistant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line ET monotherapy has a median progression-free survival (PFS) of only 2–6 months, compared to 1–4 years for first-line ET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: assessment beyond adverse event frequency
“Assessment of treatment-related toxicity should extend beyond the frequency and severity of clinician-reported adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of treatment discontinuation due to toxicity should be considered alongside patient-reported outcomes (PROs) and validated measures of health-related quality of life, including the specific domains assessed and the completeness of their reporting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: vasomotor symptoms and alopecia
“Vasomotor symptoms (VMS; also known as hot flashes) are common side effects of endocrine therapy, in particular in young women receiving LHRH analogs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Alopecia is a common distressing treatment toxicity that negatively impacts body image, quality of life and psycho-social functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, hair loss may occur with ADCs, CDK4/6 inhibitors and endocrine therapy (male-pattern androgenetic alopecia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: interstitial lung disease and cognitive impairment
“In the treatment of breast cancer, ILD has been associated with antibody drug conjugates, mTOR inhibitors, HER-2/EGFR targeted oral tyrosine kinase inhibitors, PD-1 or PD-L1 inhibitors, radiation therapy and rarely, CDK4/6 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive complaints are usually subtle or moderate, and most frequently related to ChT. However, other treatments, such as ET, targeted agents, and immunotherapy may also have an impact in cognitive function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment toxicities over sequential lines: patient-reported side effects
“Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only symptom that worsened in over 10% of the overall cohort was bone pain severity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote